Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994)
Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994)
复制标题
DOI：
10.1016/j.ejca.2004.09.030
复制
发表时间：
2005-02-01
影响因子：
8.4
通讯作者：
Zappa, M
中科院分区：
文献类型：
--
作者：
Ciatto, S;Gervasi, G;Zappa, M
前列腺癌的过度诊断率是通过1991年至1994年6890名参与者的初步筛查研究来评估的。使用癌症和死亡率登记处的数据确定观察/预期的发病率和死亡率。癌症检出率（1.75%）和观察/预期比（12.5：1）在第一次筛查时较高，在第二次筛查时显著较低（0.65%或4.10：1）。根据登记随访，整个研究队列中有225例受试者发生前列腺癌，而预期为178.2例，风险为50652例男性/年。标准化发病率在筛选组为1.66（95%CI = 1.4-2.0），在无应答者中为0.97（95%CI = 0.8-1.2），在因既往癌症或重大疾病而被排除在邀请之外的受试者中为1.23（95%CI = 0.8-1.5）。在9年的时间里，在筛选的受试者中观察到66%的过度发病率，证实了先前对过度诊断的估计。(C)2004爱思唯尔有限公司保留所有权利。
The rate of overdiagnosis of prostate carcinoma was assessed by following 6890 participants in pilot screening studies from 1991 to 1994. Observed/expected incidence and mortality were determined using data from the Cancer and Mortality Registry. The cancer detection rate (1.75%) and observed/expected ratio (12.5:1) were high at the first screening, and substantially lower at the second screening (0.65% or 4.10:1). According to the registry follow-up, prostate cancer occurred in 225 subjects in the whole study cohort, while 178.2 were expected with 50 652 men/years at risk. The standardised incidence rate was 1.66 in the screened (95%CI = 1.4-2.0), 0.97 in the non-responders (95%CI = 0.8-1.2) and 1.23 in subjects excluded from invitation due to previous cancer or major illness (95%CIl = 0.8-1.5). A 66% excess incidence rate was observed in the screened subjects over a 9-year period, confirming previous estimates of overdiagnosis. (C) 2004 Elsevier Ltd. All rights reserved.